🇺🇸 FDA
Pipeline program

IMFINZI 50 mg/mL concentrate for solution for infusion.

POSTCARD - GETUG-P13

Phase 2 small_molecule active

Quick answer

IMFINZI 50 mg/mL concentrate for solution for infusion. for oligometastatic hormone sensitive prostate cancer is a Phase 2 program (small_molecule) at CERO THERAPEUTICS HOLDINGS, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
CERO THERAPEUTICS HOLDINGS, INC.
Indication
oligometastatic hormone sensitive prostate cancer
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials